MODERNA SAYS MRNA FLU VACCINE SAILED THROUGH TRIAL, BEATING STANDARD SHOT

Summary from the TLDR newsletter

Moderna's mRNA-based seasonal flu vaccine was 27% more effective at preventing influenza infections than a standard flu shot in a study that included nearly 41,000 people aged 50 and above. The new shot, dubbed mRNA-1010, hit the highest efficacy target set for the trial. The positive results come in the wake of one of the worst flu seasons in years. An estimated 770,000 people in the US were hospitalized for the flu during the 2024-2025 flu season.